High-yield points
- NF2 is now "NF2-related schwannomatosis"; the 2021–2022 criteria include genetic and mosaic forms .
- NF1 OPG:
- in 15–20%, almost always under age 7;
- treat for vision loss with chemotherapy, not surgery .
- About 44% need second-line treatment; age under 2 and posterior location predict failure .
- Selumetinib: 70% partial response in inoperable plexiform neurofibroma and 40% in NF1 low-grade glioma .
- MPNST: 8–13% lifetime risk, presenting decades earlier than sporadic MPNST, with 21% 5-year survival. Pain or rapid growth means work it up .
- NF1 also brings moyamoya, dystrophic spine and dural ectasia .
- NF2-related schwannomatosis: bilateral vestibular schwannomas. Bevacizumab shrinks most growing tumors and improves hearing in some (4 of 7) .
Landmark papers
- SPRINT (Gross et al., N Engl J Med 2020): a phase 2 trial of selumetinib in 50 children with symptomatic inoperable plexiform neurofibromas. 70% had a confirmed partial response .
- Selumetinib in low-grade glioma (Fangusaro et al., Lancet Oncol 2019): a multicentre phase 2 trial in recurrent NF1-associated low-grade glioma. A sustained partial response occurred in 10 of 25 (40%) .
The "neurofibromatoses" are genetically distinct tumor-predisposition syndromes:
- Neurofibromatosis type 1 (NF1): a RAS–MAPK disorder caused by loss of neurofibromin.
- NF2-related schwannomatosis: formerly "neurofibromatosis type 2". The old name was retired in 2022 to improve diagnostic specificity .
- Diagnosis: both now have updated criteria that combine clinical features with genetic testing and recognize mosaic forms .
NF1
- Diagnosis: the 2021 international criteria revised the clinical features, added genetic testing, and separated NF1 from Legius syndrome (SPRED1). The two overlap in young children who have only pigmentary findings .
- Neurosurgical problems in NF1:
Optic pathway glioma (OPG)
- Epidemiology :
- seen in 15–20% of people with NF1;
- overwhelmingly in children under 7;
- many stay indolent.
- Others cause vision loss, proptosis or precocious puberty.
- Behavior: NF1-associated OPGs behave differently from sporadic ones and are managed differently .
- Screening: by ophthalmologic examination, not routine MRI.
- Treatment trigger: progressive vision loss, not imaging growth alone (see caveats).
- Chemotherapy is first-line; surgery is rarely indicated.
- Refractory or relapsed disease (103 children) :
- 44% needed two or more regimens;
- risk factors were age under 24 months at first treatment, posterior location and familial inheritance.
- MEK inhibition (selumetinib) for recurrent or progressive NF1-associated low-grade glioma :
- sustained partial response in 10 of 25 (40%).
Plexiform neurofibromas and MPNST
- Selumetinib (SPRINT, phase 2) :
- Design: 50 children with symptomatic inoperable plexiform neurofibromas.
- Result: 70% had a confirmed partial response; 28 were durable for a year or more.
- Benefit: clinically meaningful improvements in pain and function.
- Its phase 1/2 data led to the first approved drug for plexiform neurofibroma .
- Surgery: still used for symptomatic, accessible lesions and for biopsy of suspected malignant change. Complete resection is rarely possible.
- MPNST (population study) :
- lifetime risk 8–13% in NF1;
- median age 26 years in NF1 vs 62 years in sporadic cases;
- 5-year survival 21%.
- One patient developed MPNSTs in the radiation field of a prior optic glioma.
- Red flags:
- new or persistent pain;
- rapid growth;
- a change in texture;
- new neurological deficit.
- Keep a low threshold for imaging (MRI, FDG-PET) and biopsy .
- Avoid radiation in NF1 where possible because of the risk of second malignancy and vasculopathy (see caveats).
Other NF1 issues for the neurosurgeon
- Cerebral vasculopathy: moyamoya syndrome is the commonest form .
- It may be silent or present with TIA, stroke or progressive deficits.
- It can be treated medically or by revascularization (see Moyamoya).
- Spine:
- dystrophic scoliosis or kyphosis with vertebral scalloping;
- dural ectasia;
- paraspinal and dumbbell neurofibromas that compress the cord.
- Instrumentation is technically demanding because the bone is abnormal (see caveats).
- Focal areas of signal intensity ("UBOs") are common, non-enhancing and do not need treatment. An enhancing or growing lesion warrants a glioma workup.
NF2-related schwannomatosis
- Hallmark: bilateral vestibular schwannomas. Meningiomas, spinal schwannomas and intramedullary ependymomas are also common.
- Disease course (353 patients, 30 years) :
- 43.3% needed a neurosurgical or radiation treatment within 5 years of diagnosis;
- symptomatic presentation before age 16 carried worse survival;
- de novo constitutional variants did worse than mosaic or inherited disease.
- Children:
- often present with non-vestibular tumors: meningioma, spinal tumors, cataract, mononeuropathy;
- so a child with a meningioma or schwannoma should be evaluated for NF2-related schwannomatosis (see caveats).
- Bevacizumab :
- First series: 10 patients with progressive vestibular schwannomas.
- Tumors shrank in 9, and 6 had a volumetric response of 20% or more.
- Hearing improved in 4 of 7 evaluable patients.
- Shift in practice: at one center, bevacizumab use has risen while vestibular schwannoma surgery and radiotherapy have declined .
- Surgery and radiation: still needed for brainstem compression, growing meningiomas and spinal tumors, and for hearing-preservation strategies.
- Radiation is used cautiously because of the risk of malignant transformation (see caveats).
Related topics
- Optic Pathway Gliomas: NF1 versus sporadic OPG.
- Moyamoya: NF1 cerebral vasculopathy.
- Meningioma in Children: NF2 and childhood meningioma.
- Spinal Ependymoma: NF2-associated spinal ependymoma.
- Pilocytic Astrocytoma: MEK inhibition in NF1-associated low-grade glioma.
- Chiari I Malformation: Chiari in NF1.
- Tuberous Sclerosis Complex: another neurocutaneous syndrome.
- Brachial Plexus Injuries in Children: birth and traumatic plexus injuries.
References
- Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 2022;24(9):1967–1977. doi:10.1016/j.gim.2022.05.007. PMID 35674741. verified
- Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5. PMID 34012067. verified
- Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61(3):189–198. doi:10.1002/ana.21107. PMID 17387725. verified
- Kotch C, Avery R, Getz KD, et al. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol 2022;24(8):1377–1386. doi:10.1093/neuonc/noac013. PMID 35018469. verified
- Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
- Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382(15):1430–1442. doi:10.1056/NEJMoa1912735. PMID 32187457. verified
- Kotch C, de Blank P, Fangusaro J, et al. MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. Neurooncol Adv 2026;8(Suppl 2):ii14–ii24. doi:10.1093/noajnl/vdae223. PMID 42059002. verified
- Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39(5):311–314. doi:10.1136/jmg.39.5.311. PMID 12011145. verified
- Lehman LL, Ullrich NJ. Cerebral vasculopathy in children with neurofibromatosis type 1. Cancers (Basel) 2023;15(20):5111. doi:10.3390/cancers15205111. PMID 37894478. verified
- Forde C, King AT, Rutherford SA, et al. Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 2021;23(7):1113–1124. doi:10.1093/neuonc/noaa284. PMID 33336705. verified
- Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358–367. doi:10.1056/NEJMoa0902579. PMID 19587327. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the gene and pathway names;
- Legius syndrome's gene (SPRED1);
- ophthalmologic rather than MRI screening for OPG;
- treating OPG for vision loss rather than growth;
- rare surgery for OPG;
- the MPNST imaging workup (FDG-PET);
- avoiding radiation in NF1 and caution with radiation in NF2;
- the spinal findings and instrumentation difficulty;
- UBOs;
- the pediatric presentations of NF2-related schwannomatosis;
- the NF2-related tumor spectrum beyond vestibular schwannoma;
- the role of surgery for plexiform neurofibromas and the MPNST red-flag list (reference 8 supports only a low threshold for investigation).
- Reference 3 is a 2007 consensus review.
- References 8, 10 and 11 include adults.
- The figure is an original schematic.